Gliomas are the most prevalent primary malignant brain tumors in adults, with high-grade gliomas (HGGs) characterized by elevated recurrence rates, aggressiveness, and mortality. Despite numerous therapies being assessed for rHGGs, most have not yielded satisfactory results. Bevacizumab inhibits tumor angiogenesis by targeting VEGF, and garnered significant attention for its efficacy. We conducted this retrospective study to analyze the prognosis of patients with rHGG undergoing bevacizumab-related therapy, and explored the influencing factors from the clinical, radiological, and molecular pathological perspectives. Patients diagnosed with rHGGs who received bevacizumab-related therapy from January 2012 to January 2024 were included in this study. Patients were divided into bevacizumab monotherapy and combination therapy groups. Clinical, radiological, molecular pathological, and survival data were collected for analysis. A total of 162 patients diagnosed with rHGGs were enrolled, including 115 patients receiving bevacizumab monotherapy and 47 patients receiving combination therapy. The median overall survival (mOS) was 10.3 months, and the median progression-free survival (mPFS) was 5.6 months, with no statistical difference observed in mOS and mPFS between the two treatment groups. In both univariate and multivariate analysis, patients over 60 years old exhibited a worse mOS after bevacizumab-related therapy, while multiple tumors suggested a worse mPFS. This study focused on bevacizumab-related therapy in rHGGs, and the result indicated no apparent survial advantage with the addition of combination therapies to bevacizumab. Younger patients and those with single recurrent lesion were more likely to benefit from bevacizumab-related therapy. Identification of subgroups that benefit from bevacizumab-related therapy may represent a promising avenue for future research.
Wang et al. (Mon,) studied this question.